334 related articles for article (PubMed ID: 37494474)
1. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology.
Ji S; Feng L; Fu Z; Wu G; Wu Y; Lin Y; Lu D; Song Y; Cui P; Yang Z; Sang C; Song G; Cai S; Li Y; Lin H; Zhang S; Wang X; Qiu S; Zhang X; Hua G; Li J; Zhou J; Dai Z; Wang X; Ding L; Wang P; Gao D; Zhang B; Rodriguez H; Fan J; Clevers H; Zhou H; Sun Y; Gao Q
Sci Transl Med; 2023 Jul; 15(706):eadg3358. PubMed ID: 37494474
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.
Golebiewska A; Hau AC; Oudin A; Stieber D; Yabo YA; Baus V; Barthelemy V; Klein E; Bougnaud S; Keunen O; Wantz M; Michelucci A; Neirinckx V; Muller A; Kaoma T; Nazarov PV; Azuaje F; De Falco A; Flies B; Richart L; Poovathingal S; Arns T; Grzyb K; Mock A; Herold-Mende C; Steino A; Brown D; May P; Miletic H; Malta TM; Noushmehr H; Kwon YJ; Jahn W; Klink B; Tanner G; Stead LF; Mittelbronn M; Skupin A; Hertel F; Bjerkvig R; Niclou SP
Acta Neuropathol; 2020 Dec; 140(6):919-949. PubMed ID: 33009951
[TBL] [Abstract][Full Text] [Related]
3. Liver organoids: a promising three-dimensional model for insights and innovations in tumor progression and precision medicine of liver cancer.
Chen Y; Liu Y; Chen S; Zhang L; Rao J; Lu X; Ma Y
Front Immunol; 2023; 14():1180184. PubMed ID: 37334366
[TBL] [Abstract][Full Text] [Related]
4. Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine.
Joshi SK; Piehowski P; Liu T; Gosline SJC; McDermott JE; Druker BJ; Traer E; Tyner JW; Agarwal A; Tognon CE; Rodland KD
Annu Rev Pharmacol Toxicol; 2024 Jan; 64():455-479. PubMed ID: 37738504
[TBL] [Abstract][Full Text] [Related]
5. Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank.
Zhou Z; Cong L; Cong X
Front Oncol; 2021; 11():762184. PubMed ID: 35036354
[TBL] [Abstract][Full Text] [Related]
6. [Precision oncology from a proteogenomics perspective].
Huang Y; Wu S; Shu K; Zhu Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3616-3627. PubMed ID: 36305397
[TBL] [Abstract][Full Text] [Related]
7. Pan-cancer proteogenomics characterization of tumor immunity.
Petralia F; Ma W; Yaron TM; Caruso FP; Tignor N; Wang JM; Charytonowicz D; Johnson JL; Huntsman EM; Marino GB; Calinawan A; Evangelista JE; Selvan ME; Chowdhury S; Rykunov D; Krek A; Song X; Turhan B; Christianson KE; Lewis DA; Deng EZ; Clarke DJB; Whiteaker JR; Kennedy JJ; Zhao L; Segura RL; Batra H; Raso MG; Parra ER; Soundararajan R; Tang X; Li Y; Yi X; Satpathy S; Wang Y; Wiznerowicz M; González-Robles TJ; Iavarone A; Gosline SJC; Reva B; Robles AI; Nesvizhskii AI; Mani DR; Gillette MA; Klein RJ; Cieslik M; Zhang B; Paulovich AG; Sebra R; Gümüş ZH; Hostetter G; Fenyö D; Omenn GS; Cantley LC; Ma'ayan A; Lazar AJ; Ceccarelli M; Wang P;
Cell; 2024 Feb; 187(5):1255-1277.e27. PubMed ID: 38359819
[TBL] [Abstract][Full Text] [Related]
8. Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification.
Fu S; Liu X; Luo M; Xie K; Nice EC; Zhang H; Huang C
Expert Rev Proteomics; 2017 Apr; 14(4):351-362. PubMed ID: 28276747
[TBL] [Abstract][Full Text] [Related]
9. [Establishment of a living biobank : Improved guidance of precision cancer care with in vitro and in vivo cancer models].
Pauli C; Moch H; Rubin MA
Pathologe; 2017 Nov; 38(Suppl 2):160-168. PubMed ID: 28956107
[TBL] [Abstract][Full Text] [Related]
10. Refining Classification of Cholangiocarcinoma Subtypes via Proteogenomic Integration Reveals New Therapeutic Prospects.
Cho SY; Hwang H; Kim YH; Yoo BC; Han N; Kong SY; Baek MJ; Kim KH; Lee MR; Park JG; Han SS; Lee WJ; Park C; Park JB; Kim JY; Park SJ; Woo SM
Gastroenterology; 2023 Jun; 164(7):1293-1309. PubMed ID: 36898552
[TBL] [Abstract][Full Text] [Related]
11. The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment.
Rodriguez H; Zenklusen JC; Staudt LM; Doroshow JH; Lowy DR
Cell; 2021 Apr; 184(7):1661-1670. PubMed ID: 33798439
[TBL] [Abstract][Full Text] [Related]
12. Next-generation cancer organoids.
LeSavage BL; Suhar RA; Broguiere N; Lutolf MP; Heilshorn SC
Nat Mater; 2022 Feb; 21(2):143-159. PubMed ID: 34385685
[TBL] [Abstract][Full Text] [Related]
13. Organoids as research models for hepatocellular carcinoma.
Yu JH; Ma S
Exp Cell Res; 2022 Feb; 411(1):112987. PubMed ID: 34942189
[TBL] [Abstract][Full Text] [Related]
14. Proteogenomic interrogation of cancer cell lines: an overview of the field.
Tsang O; Wong JWH
Expert Rev Proteomics; 2021 Mar; 18(3):221-232. PubMed ID: 33877947
[No Abstract] [Full Text] [Related]
15. Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages.
Ng CKY; Dazert E; Boldanova T; Coto-Llerena M; Nuciforo S; Ercan C; Suslov A; Meier MA; Bock T; Schmidt A; Ketterer S; Wang X; Wieland S; Matter MS; Colombi M; Piscuoglio S; Terracciano LM; Hall MN; Heim MH
Nat Commun; 2022 May; 13(1):2436. PubMed ID: 35508466
[TBL] [Abstract][Full Text] [Related]
16. Proteogenomic characterization of cholangiocarcinoma.
Deng M; Ran P; Chen L; Wang Y; Yu Z; Cai K; Feng J; Qin Z; Yin Y; Tan S; Liu Y; Xu C; Shi G; Ji Y; Zhao JY; Zhou J; Fan J; Hou Y; Ding C
Hepatology; 2023 Feb; 77(2):411-429. PubMed ID: 35716043
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer.
Xian L; Zhao P; Chen X; Wei Z; Ji H; Zhao J; Liu W; Li Z; Liu D; Han X; Qian Y; Dong H; Zhou X; Fan J; Zhu X; Yin J; Tan X; Jiang D; Yu H; Cao G
Cell Oncol (Dordr); 2022 Oct; 45(5):1019-1036. PubMed ID: 36036881
[TBL] [Abstract][Full Text] [Related]
18. Progress in patient-derived liver cancer cell models: a step forward for precision medicine.
Zhang Z; Hui L
Acta Biochim Biophys Sin (Shanghai); 2023 Nov; 55(11):1707-1717. PubMed ID: 37766458
[TBL] [Abstract][Full Text] [Related]
19. Methods, Tools and Current Perspectives in Proteogenomics.
Ruggles KV; Krug K; Wang X; Clauser KR; Wang J; Payne SH; Fenyö D; Zhang B; Mani DR
Mol Cell Proteomics; 2017 Jun; 16(6):959-981. PubMed ID: 28456751
[TBL] [Abstract][Full Text] [Related]
20. Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity.
Bruun J; Kryeziu K; Eide PW; Moosavi SH; Eilertsen IA; Langerud J; Røsok B; Totland MZ; Brunsell TH; Pellinen T; Saarela J; Bergsland CH; Palmer HG; Brudvik KW; Guren T; Dienstmann R; Guren MG; Nesbakken A; Bjørnbeth BA; Sveen A; Lothe RA
Clin Cancer Res; 2020 Aug; 26(15):4107-4119. PubMed ID: 32299813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
